Discontinuation of antiretroviral therapy postpartum: No evidence for altered viral set point [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 1, 2007, Pages 116-117

  Tungsiripat, Marisa ^a   Drechsler, Henning ^b   Aberg, Judith A ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; CONTROLLED STUDY; DEATH; DELIVERY; DISEASE COURSE; DRUG SUBSTITUTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; MONOTHERAPY; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RISK; TREATMENT WITHDRAWAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PATIENT DROPOUTS; POSTPARTUM PERIOD; PREGNANCY; RETROSPECTIVE STUDIES; TREATMENT REFUSAL; VIRAL LOAD;

EID: 33846029515     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31802b9695     Document Type: Letter

References (11)

1. El-Sadr W, Neaton J. Episodic CD4-guided use of antiretroviral therapy is inferior to continuous therapy: results of the SMART study [abstract 196LB]. Presented at: 13th Conference of Retroviruses and Opportunistic Infections; 2006; Denver.
2. Danel C, Moh R, Sorho S, et al. The CD4-guided strategy arm stopped in a randomized structured treatment interruption trial in West African adults: ANRS 1269 Trivacan Trial [abstract 105 LB]. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver.
3. Palmisano L, Giuliano M, Bucciardini R. Final results of a randomized, controlled trial of structured treatment interruptions vs. continuous HAART in chronic HIV-infected subjects with persistent suppression of viral replication [abstract 104]. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver.
4. Alliegro MB, Dorrucci M, Phillips AN, et al. Incidence and consequences of pregnancy in women with known duration of HIV infection. Italian Seroconversion Study Group. Arch Intern Med. 1997;157:2585-2590.
5. Hocke C, Morlat P, Chene G, et al. Prospective cohort study of the effect of pregnancy on the progression of human immunodeficiency virus infection. The Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. Obstet Gynecol. 1995;86:886-891.
6. Temmerman M, Chomba EN, Ndinya-Achola J, et al. Maternal human immunodeficiency virus-1 infection and pregnancy outcome. Obstet Gynecol. 1994;83:495-501.
7. Watts DH, Lambert J, Stiehm ER, et al. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr. 2003;33:585-593.
8. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med. 1997;3:549-552.
9. Melvin AJ, Burchett SK, Watts DH, et al. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:232-236.
10. Burns DN, Landesman S, Minkoff H, et al. The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. Am J Obstet Gynecol. 1998;178:355-359.
11. Bardequez A, Lindsey J, Shannon M. Adherence to ART in US women during and after pregnancy [abstract 706]. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver.